China Oncology ›› 2022, Vol. 32 ›› Issue (10): 1000-1006.doi: 10.19401/j.cnki.1007-3639.2022.10.008
• Review • Previous Articles Next Articles
CAO Dalong1,2(), YE Dingwei1,2()
Received:
2022-06-02
Revised:
2022-10-19
Online:
2022-10-30
Published:
2022-11-29
CLC Number:
CAO Dalong, YE Dingwei. New trends and future prospects of regulatory cell death in renal carcinoma[J]. China Oncology, 2022, 32(10): 1000-1006.
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660 |
[2] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.21492 |
[3] | ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. |
[4] |
CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
doi: 10.3322/caac.21338 |
[5] |
COHEN H T, MCGOVERN F J. Renal-cell carcinoma[J]. N Engl J Med, 2005, 353(23): 2477-2490.
doi: 10.1056/NEJMra043172 |
[6] |
POWLES T, PLIMACK E R, SOULIÈRES D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573.
doi: 10.1016/S1470-2045(20)30436-8 pmid: 33284113 |
[7] |
MOTZER R J, TANNIR N M, MCDERMOTT D F, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290.
doi: 10.1056/NEJMoa1712126 |
[8] |
FUCHS Y, STELLER H. Programmed cell death in animal development and disease[J]. Cell, 2011, 147(4): 742-758.
doi: 10.1016/j.cell.2011.10.033 pmid: 22078876 |
[9] |
TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.
doi: 10.1126/science.abf0529 pmid: 35298263 |
[10] |
LI J, CAO F, YIN H L, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88.
doi: 10.1038/s41419-020-2298-2 pmid: 32015325 |
[11] | FANG Y, TIAN S W, PAN Y T, et al. Pyroptosis: a new frontier in cancer[J]. Biomedecine Pharmacother, 2020, 121: 109595. |
[12] |
LEVY J M M, TOWERS C G, THORBURN A. Targeting autophagy in cancer[J]. Nat Rev Cancer, 2017, 17(9): 528-542.
doi: 10.1038/nrc.2017.53 pmid: 28751651 |
[13] |
CARNEIRO B A, EL-DEIRY W S. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(7): 395-417.
doi: 10.1038/s41571-020-0341-y pmid: 32203277 |
[14] |
DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
doi: 10.1016/j.cell.2012.03.042 pmid: 22632970 |
[15] |
DOLMA S, LESSNICK S L, HAHN W C, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer Cell, 2003, 3(3): 285-296.
pmid: 12676586 |
[16] |
ZHOU B R, LIU J, KANG R, et al. Ferroptosis is a type of autophagy-dependent cell death[J]. Semin Cancer Biol, 2020, 66: 89-100.
doi: S1044-579X(19)30006-9 pmid: 30880243 |
[17] |
LEI G, ZHUANG L, GAN B Y. Targeting ferroptosis as a vulnerability in cancer[J]. Nat Rev Cancer, 2022, 22(7): 381-396.
doi: 10.1038/s41568-022-00459-0 pmid: 35338310 |
[18] |
YANG W S, SRIRAMARATNAM R, WELSCH M E, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1/2): 317-331.
doi: 10.1016/j.cell.2013.12.010 |
[19] |
MIESS H, DANKWORTH B, GOUW A M, et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma[J]. Oncogene, 2018, 37(40): 5435-5450.
doi: 10.1038/s41388-018-0315-z pmid: 29872221 |
[20] |
YANG W H, DING C K C, SUN T A, et al. The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma[J]. Cell Rep, 2019, 28(10): 2501-2508.e4.
doi: 10.1016/j.celrep.2019.07.107 |
[21] |
LEE H, ZANDKARIMI F, ZHANG Y L, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis[J]. Nat Cell Biol, 2020, 22(2): 225-234.
doi: 10.1038/s41556-020-0461-8 pmid: 32029897 |
[22] |
LU Y Q, QIN H X, JIANG B, et al. KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma[J]. Cancer Lett, 2021, 522: 1-13.
doi: 10.1016/j.canlet.2021.09.014 pmid: 34520818 |
[23] |
KERINS M J, MILLIGAN J, WOHLSCHLEGEL J A, et al. Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction[J]. Cancer Sci, 2018, 109(9): 2757-2766.
doi: 10.1111/cas.13701 |
[24] |
COOKSON B T, BRENNAN M A. Pro-inflammatory programmed cell death[J]. Trends Microbiol, 2001, 9(3): 113-114.
pmid: 11303500 |
[25] |
LIU X, ZHANG Z B, RUAN J B, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores[J]. Nature, 2016, 535(7610): 153-158.
doi: 10.1038/nature18629 |
[26] |
SHI J J, GAO W Q, SHAO F. Pyroptosis: gasdermin-mediated programmed necrotic cell death[J]. Trends Biochem Sci, 2017, 42(4): 245-254.
doi: S0968-0004(16)30182-7 pmid: 27932073 |
[27] |
KAYAGAKI N, WONG M T, STOWE I B, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4[J]. Science, 2013, 341(6151): 1246-1249.
doi: 10.1126/science.1240248 pmid: 23887873 |
[28] |
LAGRANGE B, BENAOUDIA S, WALLET P, et al. Human caspase-4 detects tetra-acylated LPS and cytosolic Francisella and functions differently from murine caspase-11[J]. Nat Commun, 2018, 9(1): 242.
doi: 10.1038/s41467-017-02682-y pmid: 29339744 |
[29] |
WANG Y P, GAO W Q, SHI X Y, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature, 2017, 547(7661): 99-103.
doi: 10.1038/nature22393 |
[30] |
HOU J W, ZHAO R C, XIA W Y, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis[J]. Nat Cell Biol, 2020, 22(10): 1264-1275.
doi: 10.1038/s41556-020-0575-z pmid: 32929201 |
[31] |
WEI X, XIE F, ZHOU X X, et al. Role of pyroptosis in inflammation and cancer[J]. Cell Mol Immunol, 2022, 19(9): 971-992.
doi: 10.1038/s41423-022-00905-x pmid: 35970871 |
[32] |
SUN Z L, JING C Y, GUO X D, et al. Comprehensive analysis of the immune infiltrates of pyroptosis in kidney renal clear cell carcinoma[J]. Front Oncol, 2021, 11: 716854.
doi: 10.3389/fonc.2021.716854 |
[33] |
YAO L, LI J N, XU Z J, et al. GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma[J]. Aging, 2022, 14(6): 2758-2774.
doi: 10.18632/aging.203973 |
[34] | TANG X F, ZHANG A N, FENG Y Y, et al. A novel pyroptosis-related lncRNAs signature for predicting the prognosis of kidney renal clear cell carcinoma and its associations with immunity[J]. J Oncol, 2021, 2021: 9997185. |
[35] |
TAN Y F, WANG M, CHEN Z Y, et al. Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis[J]. Cell Death Dis, 2020, 11(4): 239.
doi: 10.1038/s41419-020-2431-2 |
[36] |
CHOI A M, RYTER S W, LEVINE B. Autophagy in human health and disease[J]. N Engl J Med, 2013, 368(7): 651-662.
doi: 10.1056/NEJMra1205406 |
[37] |
LEVINE B, KROEMER G. Biological functions of autophagy genes: a disease perspective[J]. Cell, 2019, 176(1/2): 11-42.
doi: 10.1016/j.cell.2018.09.048 |
[38] |
ALESSANDRINI F, PEZZÈ L, CIRIBILLI Y. LAMPs: shedding light on cancer biology[J]. Semin Oncol, 2017, 44(4): 239-253.
doi: S0093-7754(17)30046-5 pmid: 29526252 |
[39] |
ZHAO Y, CODOGNO P, ZHANG H. Machinery, regulation and pathophysiological implications of autophagosome maturation[J]. Nat Rev Mol Cell Biol, 2021, 22(11): 733-750.
doi: 10.1038/s41580-021-00392-4 |
[40] | RUSSELL R C, GUAN K L. The multifaceted role of autophagy in cancer[J]. EMBO J, 2022, 41(13): e110031. |
[41] |
LEBOVITZ C B, ROBERTSON A G, GOYA R, et al. Cross-cancer profiling of molecular alterations within the human autophagy interaction network[J]. Autophagy, 2015, 11(9): 1668-1687.
doi: 10.1080/15548627.2015.1067362 pmid: 26208877 |
[42] |
KANG J H, LEE J S, HONG D, et al. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy[J]. Cell Death Dis, 2016, 7: e2163.
doi: 10.1038/cddis.2016.14 |
[43] |
TURCOTTE S, CHAN D A, SUTPHIN P D, et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy[J]. Cancer Cell, 2008, 14(1): 90-102.
doi: 10.1016/j.ccr.2008.06.004 pmid: 18598947 |
[44] |
YANG X Q, ZHANG Y Y, FAN H Y. Downregulation of SBF2-AS1 functions as a tumor suppressor in clear cell renal cell carcinoma by inhibiting miR-338-3p-targeted ETS1[J]. Cancer Gene Ther, 2021, 28(7/8): 813-827.
doi: 10.1038/s41417-020-0197-4 |
[45] |
LIANG X Y, DE VERA M E, BUCHSER W J, et al. Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression[J]. Cancer Res, 2012, 72(11): 2791-2801.
doi: 10.1158/0008-5472.CAN-12-0320 pmid: 22472122 |
[46] |
PIETROCOLA F, POL J, VACCHELLI E, et al. Caloric restriction mimetics enhance anticancer immunosurveillance[J]. Cancer Cell, 2016, 30(1): 147-160.
doi: S1535-6108(16)30221-5 pmid: 27411589 |
[47] |
ZHANG T, WANG Y N, INUZUKA H, et al. Necroptosis pathways in tumorigenesis[J]. Semin Cancer Biol, 2022, 86(Pt 3): 32-40.
doi: 10.1016/j.semcancer.2022.07.007 |
[48] |
ZHAO C, ZHOU Y F, RAN Q, et al. microRNA-381-3p functions as a dual suppressor of apoptosis and necroptosis and promotes proliferation of renal cancer cells[J]. Front Cell Dev Biol, 2020, 8: 290.
doi: 10.3389/fcell.2020.00290 pmid: 32411707 |
[49] |
MAO Q Y, ZHUANG Q F, SHEN J, et al. MiRNA-124 regulates the sensitivity of renal cancer cells to cisplatin-induced necroptosis by targeting the CAPN4-CNOT3 axis[J]. Transl Androl Urol, 2021, 10(9): 3669-3683.
doi: 10.21037/tau-21-777 pmid: 34733662 |
[50] | WANG K J, MENG X Y, CHEN J F, et al. Emodin induced necroptosis and inhibited glycolysis in the renal cancer cells by enhancing ROS[J]. Oxid Med Cell Longev, 2021, 2021: 8840590. |
[51] |
BRADLEY J R, WANG J, PACEY S, et al. Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133+ cells in clear cell renal carcinoma[J]. FASEB Bioadvances, 2020, 2(2): 126-144.
doi: 10.1096/fba.2019-00071 |
[1] | SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis [J]. China Oncology, 2022, 32(4): 287-297. |
[2] | Diao Xinfeng, Li Xinmao, Hou Liang, Wei Zhixuan. YTHDF2 promotes progression of glioblastoma via inducing mRNA decay of IGFBP7 and activating PI3K/AKT signaling pathway [J]. China Oncology, 2022, 32(3): 218-227. |
[3] | ZHANG Jiaxiang, ZHOU Yongxue, YAN Shuguang, ZHAO Weihan, DONG Fen. Research progress of hypoxia-induced mitochondrial autophagy and glucose metabolism reprogramming in gastric precancerous lesions [J]. China Oncology, 2022, 32(10): 1007-1015. |
[4] | CHEN Yifan, SHEN Yihui, CHENG Leilei, LIN Jinyi, ZHANG Hui, WANG Xuejun, XU Yuchen, ZHANG Jian, GE Junbo. Different preventive effects of four cardioprotective agents on mice with adriamycin-induced cardiotoxicity [J]. China Oncology, 2022, 32(10): 936-947. |
[5] | JIA Zhenzhen, HE Shuang, LI Yangyang, WEN Feifei, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlations between expressions of DPD, LC3 and P62 in colorectal cancer and their clinical significance [J]. China Oncology, 2022, 32(1): 24-33. |
[6] | LEI Kunyang, XIE Wenjie, SUN Ting, LIU Yifu, WANG Xu. Expression and effect of long non-coding RNA ARAP1-AS1 in clear cell renal cell carcinoma [J]. China Oncology, 2022, 32(1): 34-40. |
[7] | LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun . miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene [J]. China Oncology, 2021, 31(7): 581-588. |
[8] | CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei. The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells [J]. China Oncology, 2021, 31(6): 441-446. |
[9] | HUA Qing, SHEN Xuefang, XU Pingbo . Effect of KLK8 on apoptosis of colorectal cancer cells by regulating EGF and its mechanism [J]. China Oncology, 2021, 31(5): 383-389. |
[10] | CHEN Guo , HAN Pengli , CHEN Keru , LI Mingchuang , ZHANG Qingsong , CHEN Zheng , DONG Hanhua , QIAN Yuejun , LÜ Jing . Molecular mechanism of miR-19b-3p regulating apoptosis of medullary thyroid cancer cells by targeting MTUS1 [J]. China Oncology, 2021, 31(5): 390-396. |
[11] | CHEN Shaogeng, HE Rongqi, ZHANG Wanfei, LIN Xianzuan, CHEN Heshan, XU Rongyu. miR-122-5p inhibits the growth of esophageal cancer cells and transplanted tumors by targeting CREB1 [J]. China Oncology, 2021, 31(1): 35-44. |
[12] | OUYANG Xiaochun , ZOU Yeqing , LI Yumei , DING Xiaobing . ARHGAP4 promotes growth of hepatocellular carcinoma cells by regulating HK2 expression [J]. China Oncology, 2020, 30(7): 481-487. |
[13] | WANG Fang , WANG Xin , LIU Zhe , HUI Lingyun , FENG Ai , LI Na , WANG Yawen . Inhibition of PDK1 induces apoptosis in CML cells via activation of ASK1/JNK/Bim cascade [J]. China Oncology, 2020, 30(6): 401-406. |
[14] | TONG Ying, YU Yiwen, XIE Suhong, WANG Yanchun, LU Renquan, GUO Lin. Effects of silent information regulator 4 overexpression or glutamine deprivation on apoptosis and proliferation of clear cell renal cell carcinoma [J]. China Oncology, 2020, 30(6): 435-440. |
[15] | LIU Peng , GONG Yang , LIU Daojiang , ZHANG Xiang , ZHANG Jianan , YANG Gaoliang , FANG Nian . A study on the expression of PFKFB3 in gastric cancer and its effect on the growth and apoptosis of gastric cancer cells [J]. China Oncology, 2020, 30(4): 268-274. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd